Closed · W81XWH-16-NFRP-CCA · CFDA 12.420 · Discretionary

DoD Neurofibromatosis Clinical Consortium Award

Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.

Varies
Award range
Closed
Status
August 1, 2016
Close date
1
Expected awards

The verdict

DoD Neurofibromatosis Clinical Consortium Award is a closed discretionary listing from Defense Health Agency Contracting Activity - DHACA that offered Varies by applicant across 1 expected award. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 1,795 other opportunities from Defense Health Agency Contracting Activity - DHACA.

Varies
award range
Closed
application status
1
expected award
12.420
CFDA program

Archived opportunity record

DoD Neurofibromatosis Clinical Consortium Awa… is closed (last close August 1, 2016). Check the agency catalog for replacement NOFOs. Defense Health Agency Contracting Activity - DHACA still indexes 1,795 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed August 1, 2016

Posted May 6 Closes Aug 1

Est. Total Funding

$5,000,000

Expected Awards

1

Instrument

Grant

Description

The FY16 NFRP Clinical Consortium Award is intended to support a major goal/product-driven Consortium of exceptional institutions and investigators that will accelerate the clinical translation of basic NF research and ultimately decrease the impact of the disease. The objectives of the Consortium shall be to conceive, design, develop, and conduct collaborative Phase I and II clinical evaluations of promising therapeutic agents for the management or treatment of NF1, NF2, and schwannomatosis. The NF Clinical Consortium needs to be a collaboration of multiple organizations and individuals for the purpose of rapidly executing clinical trials. The Consortium must consist of a single Operations Center and a minimum of five Clinical Trial Sites with a demonstrated history of collaborative research. The participants will be jointly responsible for prioritizing, proposing, conducting, and analyzing Phase I and Phase II clinical trials focused on therapeutic interventions for NF1, NF2, and schwannomatosis. The Operations Center and associated Clinical Trial Sites must apply to this announcement through a single application submitted by the Operations Center. The Operations Center may also serve as a trial site. A single award will be made to the Operations Center. Award funds are to be used to support the Operations Center’s efforts as well as Consortium-associated studies at through the appropriate subcontract or other instruments for the Clinical Trial Sites. Award selection will be based on evaluation of the proposed plans for initial clinical trials to be implemented, available capabilities, organization of the Consortium, and feasibility of the collective group to accomplish the overall award objectives (see Section III.B., Application Review Process). During the performance period of the award, the Operations Center and all Clinical Trial Sites will be responsible for working collaboratively to identify new clinical trials for implementation by the Consortium. The NFRP is allocating a total of $9M in support of the Consortium. The Consortium will be funded initially for a total of $5M with allocations from the FY16 NFRP Congressional appropriation. Two additional option periods, to be included in the application, will be funded for a total of $2M each (minimum of 1 trial per option must be proposed), subject to receipt of future Congressional appropriations. See Section I.D., Funding, for additional information.

Catch-all / unrestricted eligibility mark · W81XWH-16-NFRP-CCA

Grants.gov marks DoD Neurofibromatosis Clinical Consortium Awa… with a catch-all / unrestricted eligibility code (Unrestricted / see official listing). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity code maps to Science and Technology / R&D (ST). This eligibility-code string dominates the Defense Health Agency Contracting Activity - DHACA book (1,791 peers, 100% of 1,796).

Code 99
Unrestricted / see official listing

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org

What to do next

DoD Neurofibromatosis Clinical Consortium Awa… is closed; use the parent program and agency catalog for the next funding cycle.

  • Browse open federal opportunities in the same category when this listing is closed. Open opportunities
  • Look up CFDA 12.420 across all indexed listings before you commit to this opportunity alone. Eligibility finder
  • Compare award ranges across federal categories before you pick a single CFDA. All categories

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants